Intensity Therapeutics, Inc. reported a net loss of $16.3 million for the year ended December 31, 2024, an increase from $10.5 million in 2023. Research and development expenses significantly increased to $10.5 million from $4.8 million, primarily due to the initiation and progress of the INVINCIBLE-3 and INVINCIBLE-4 studies. General and administrative expenses also rose to $6.1 million from $3.5 million, driven by higher personnel, legal, and insurance costs.
As of December 31, 2024, cash and cash equivalents totaled $2.6 million. The company continues to operate with net losses and negative cash flows, typical for a clinical-stage biotechnology company, underscoring its reliance on external capital.
Despite financial challenges, the company advanced its clinical pipeline. The Phase 3 INVINCIBLE-3 sarcoma study, which dosed its first patient in July 2024, is actively enrolling patients across multiple countries and expects to complete enrollment in the first half of 2026. The Phase 2 INVINCIBLE-4 breast cancer study, initiated in October 2024, has activated eight sites in Switzerland and treated several patients, with enrollment expected to complete by the end of the first quarter of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.